Form 4: 2seventy bio, Inc. Executive Jessica Snow Disposes of Shares and Options Following Merger with Bristol-Myers Squibb

Jessica Snow, Chief Operating Officer of 2seventy bio, Inc., reports the disposition of common stock and stock options due to the merger with Bristol-Myers Squibb Company.

Summary

• Jessica Snow, the Chief Operating Officer of 2seventy bio, Inc., filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the disposal of common stock and stock options as a result of the merger between 2seventy bio, Inc. and Bristol-Myers Squibb Company, which became effective on May 13, 2025.
• The merger involved Bristol-Myers Squibb acquiring all outstanding shares of 2seventy bio at a price of $5.00 per share.
• Snow disposed of 247,230 shares of common stock.
• She also disposed of stock options with exercise prices of $3.97 (18,300 options) and $2.64 (70,750 options).
• Restricted stock units held by Snow became fully vested and were converted into the right to receive cash equal to the merger consideration for each underlying share.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports the execution of a previously announced merger agreement. There are no indications of unexpected positive or negative outcomes.

Future Outlook

The merger between 2seventy bio, Inc. and Bristol-Myers Squibb Company is complete, with 2seventy bio now operating as a wholly-owned subsidiary of Bristol-Myers Squibb.

Industry Context

This merger reflects a trend in the biotechnology industry where larger pharmaceutical companies acquire smaller, innovative firms to expand their pipelines and capabilities. Bristol-Myers Squibb's acquisition of 2seventy bio is likely aimed at strengthening its position in cell therapy or related fields.

Comparison to Industry Standards

• Acquisitions in the biotech industry often involve a premium paid over the target company's existing share price, reflecting the value of their intellectual property and potential future earnings.
• The $5.00 per share merger consideration should be compared to the trading price of TSVT prior to the announcement to assess the premium received by shareholders.
• Similar acquisitions, such as Gilead's acquisition of Kite Pharma, demonstrate the strategic importance of cell therapy assets to major pharmaceutical companies.

Stakeholder Impact

• Shareholders of 2seventy bio received $5.00 per share as part of the merger agreement.
• Employees of 2seventy bio may experience changes as the company integrates into Bristol-Myers Squibb.

Key Dates

Keywords

Form 4, Merger, Disposition, Stock Options, Common Stock, 2seventy bio, Bristol-Myers Squibb, Jessica Snow